Free Articles
Free to read — no membership required.
I Have APOE4. What Do I Do Now?
Written for someone who has just received an APOE4 result and does not yet know what it means — what the genotype does, what it does not, and the actions that have evidence behind them.
What APOE4 Means: A Practical Guide for Patients
What carrying one or two copies of APOE ε4 means for your brain, your risk, and the decisions in front of you — in plain language.
APOE 2, 3, and 4: What the Three Versions of This Gene Actually Do
Three versions of one gene, separated by two amino acids — and why that small difference sends Alzheimer’s risk in three different directions.
APOE ε4 Risk Is Not the Same in Every Population
The widely quoted risk figures come almost entirely from people of European ancestry. How much the numbers change elsewhere, and the haplotype explanation for why.
DHA and Brain Health: A Guide for APOE ε4 Carriers
Timing and molecular form both matter. What the DHA trials show for carriers before symptoms begin, and what they show after.
APOE ε4 or ApoE4? A Clinician’s Guide to Correct Nomenclature
Gene, allele, protein isoform, and search term are four different things. A short reference for using each correctly in writing and in clinic.
Stem Cells, Exosomes, and Peptides for Alzheimer’s Disease: What the Evidence Shows
A clinical review of regenerative therapies marketed to APOE ε4 carriers — what randomized evidence actually supports, and where it doesn’t.
The End of Alzheimer’s Program: A Neurologist’s Review
A board-certified neurologist and APOE ε4 carrier reviews Dale Bredesen’s bestselling protocol — what the evidence supports, and where it overclaims.
No More Sleepless Nights: A Neurologist’s Review
A physician’s review of a popular sleep program, and what the evidence actually says about sleep and APOE ε4 risk.
Why Some Scientists Question the Amyloid Hypothesis
Why the leading theory of Alzheimer’s disease is being challenged — and why it doesn’t change what APOE ε4 carriers should do.
Alzheimer’s Treatments and Emerging Therapies: A Guide for APOE ε4 Carriers
Current FDA-approved therapies, what’s in clinical trials, and what APOE ε4 status means for treatment candidacy.
Navigating Pre-Death Grief: Managing the Emotional Toll of Dementia Caregiving
The grief that begins long before the death does — why it is so often unrecognized, and what helps caregivers carry it.
Key Considerations After a Dementia Diagnosis in APOE ε4 Carriers
The decisions that matter most in the first months after a diagnosis, and the ones that can safely wait.
Who Helps After a Dementia Diagnosis? Building Your Care Team
Who belongs on the care team after a dementia diagnosis — and how to actually find a geriatric psychiatrist or social worker.
Intermittent Fasting: A Patient Guide
What intermittent fasting has been shown to do for brain aging, what remains mechanistic only, and who should not attempt it.
APOE ε4 Carriers and Meat
Dietary meat intake and cognitive outcomes in APOE ε4 carriers, and what the observational data can and cannot establish.
Member-Only Articles
Full clinical reviews and evidence tables. Become a member to unlock the complete library.
-
Physician Conversation Guides: Four Frameworks for APOE ε4 Carriers
A typical primary care visit runs fifteen minutes, and most clinicians encounter APOE results rarely and without clinical…
-
Intervention Strategies for APOE ε4 Carriers: Ranking the Evidence, Including What Failed
Two randomized trials have now tested whether APOE ε4 carriers benefit more from multidomain lifestyle intervention than non-carriers.…
-
Laboratory Assessment for APOE ε4 Carriers: What the Evidence Supports
In 4,807 older adults, statin initiation was associated with a 40% lower risk of incident Alzheimer disease among…
-
APOE ε2, ε3, and ε4: How Two Amino Acid Substitutions Produce Three Different Clinical Phenotypes
LDL cholesterol rises linearly across APOE genotype, but coronary risk does not follow it. Bennet et al. (JAMA…
-
Can APOE4 Risk Be Normalized? A Clinical Review
A clinical review of whether APOE ε4-associated risk can be normalized through modifiable intervention — examining multidomain prevention…
-
The ε4/ε4 Carriers Who Do Not Develop Alzheimer’s: Resistance and Resilience
A minority of APOE ε4 homozygotes reach advanced age without dementia. This review examines the distinction between resistance…
-
Alzheimer’s Blood Tests vs. APOE Genetic Testing: Two Different Questions
An Alzheimer’s blood biomarker and an APOE genotype test answer fundamentally different clinical questions: one indicates whether disease…
-
Exercise and Your Brain: What the Muscle-Brain Axis Means for You
A patient-facing explanation of the muscle-brain axis — how skeletal muscle signals to the brain during exercise, which…
-
The Muscle-Brain Axis: Mechanisms and Implications for APOE ε4 Carriers
The mechanistic basis of exercise-induced neuroprotection — myokine signaling, neurotrophic pathways, and metabolic effects — with explicit attention…